Takeda: Gaucher Disease trials

The registry lists 20 Gaucher Disease studies with Takeda as lead sponsor. 2 are open to participants now and 12 have results posted.

Phase 1 2Phase 2 3Phase 3 7Phase 4 2No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velaglucerase Alfa (VPRIV) Home InfusionNot yet recruitingNCT05669729
• Gaucher Disease Outcome Survey (GOS)RecruitingNCT03291223
• A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher DiseaseCompletedNCT05529992Phase 3Results posted
• A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction TherapyCompletedNCT04718779Phase 4Results posted
• Survey Study for Velaglucerase Alfa (VPRIV) in JapanCompletedNCT03625882Results posted
• Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher DiseaseCompletedNCT02574286Phase 4Results posted
• Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher DiseaseCompletedNCT01842841Phase 3Results posted
• Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher DiseaseCompletedNCT01685216Phase 1/2Results posted
• Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher DiseaseCompletedNCT01614574Phase 3Results posted
• An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher DiseaseCompletedNCT00635427Phase 3Results posted
• Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher DiseaseCompletedNCT00553631Phase 3Results posted
• Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With ImigluceraseCompletedNCT00478647Phase 2/3Results posted
• A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher DiseaseCompletedNCT00430625Phase 3Results posted
• Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)CompletedNCT00391625Phase 1/2Results posted
• A Study Measuring Substances Potentially Indicating Bone Problems in Adults With Type 1 Gaucher ConditionCompletedNCT05702814
• A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young Children With Gaucher DiseaseCompletedNCT04721366
• Post Marketing Surveillance (PMS) Study for Velaglucerase Alfa (VPRIV) in IndiaCompletedNCT04429984
• A Study of VPRIV in Participants With Gaucher Disease Previously Treated With Other Enzyme Replacement Therapies or Substrate Reduction TherapiesTerminatedNCT04094181
• Home Therapy With VPRIV in Gaucher's DiseaseCompletedNCT01356537
• Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher DiseaseApproved for marketingNCT00954460